New findings suggest that late-onset Alzheimer’s Disease is driven by epigenetic changes—how and when certain genes are turned on and off—in the brain. Results were published in Nature Genetics.
Research led by Raffaella Nativio, a former research associate of epigenetics, Shelley Berger, a professor of genetics, biology and cell and developmental diology and director of the Epigenetics Institute, and Nancy Bonini, a professor of biology and cell and developmental biology, all in the Perelman School of Medicine at the University of Pennsylvania, used post-mortem brain tissue to compare healthy younger and older brain cells to those with Alzheimer’s disease. The team found evidence that epigenetic regulators disable protective pathways and enable pro-disease pathways in those with the disease.
“The last five years have seen great efforts to develop therapeutics to treat Alzheimer’s disease, but sadly, they have failed in the clinic to treat humans suffering from this horrible disease,” Berger said. “We are trying a completely different approach to reveal the critical changes in brain cells, and our findings show epigenetic changes are driving disease.”
Epigenetic changes alter gene expression without DNA mutation, but rather by marking proteins that package and protect DNA, called histones. Berger added, “the activity of epigenetic regulators can be inhibited by drugs, and hence we are excited that this may be an Achilles’ heel of Alzheimer’s that can be attacked by new therapeutics.”
In this study, the researchers integrated many large-scale cutting-edge approaches of RNA, protein, and epigenomic analyses of postmortem human brains to interrogate the molecular pathways involved in Alzheimer’s. They found upregulation of transcription- and chromatin-related genes, including of central histone acetyltransferases for marks that open up the chromatin (marks called acetylation of lysine 27 and 9 on histone H3, or H3K27ac and H3K9ac). Proteomic screening also singled out these marks as enriched in Alzheimer’s. The findings were tested functionally in a fly Drosophila model, to show that increasing these marks exacerbated Alzheimer’s Disease associated effects.
“Based on our findings, there is a reconfiguration of the epigenomic landscape—that’s the DNA genome plus associated proteins—normally with age in the brain,” Bonini said. “These changes fail to occur in Alzheimer’s and instead other changes occur. What’s remarkable is that the simple fruit fly Drosophila, in which we can express Alzheimer’s associated proteins and confer an Alzheimer’s effect, confirms that the specific types of changes to the epigenome we predict are associated with Alzheimer’s do exaggerate the toxicity of Alzheimer’s proteins.”
These findings suggest that Alzheimer’s Disease involves a reconfiguration of the epigenomic landscape, with the marks H3K27ac and H3K9ac affecting disease pathways by disrupting transcription- and chromatin–gene feedback loops. The identification of this process highlights potential strategies to modulate these marks for early-stage disease treatment.
This research built off a previous study published by the team in 2018. Like this study, they compared the epigenomic landscape of disease to both younger and elderly cognitively normal control subjects. The team described the genome-wide enrichment of another acetylation mark of acetylation of lysine 16 on histone H4 (H4K16ac). H4K16ac is a key modification in human health because it regulates cellular responses to stress and to DNA damage. The team found that, while normal aging leads to increasing H4K16ac in new positions along the genome and an increase in where it is already present, in great contrast, Alzheimer’s entails losses of H4K16ac in the proximity of genes linked to aging and disease.
“Overall we found in the previous study that certain acetylation marks protect the brain during normal aging, whereas, strikingly, in our new study, we found that other acetylation marks drive disease. The next step is to identify mechanisms underlying the protective and degradative pathways, which will lead to a more targeted approach for Alzheimer’s Disease therapy,” Nativio said.
Additional co-authors from the University of Pennsylvania include Yemin Lan, Greg Donahue, Simon Sidoli, Ananth Srinivasan, Alexandre Amlie-Wolf, Li-San Wang, Ben Garcia, and John Trojanowski.
This work received funding from the Kleberg Foundation and the National Institutes of Health.
